Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.33USD
3:59pm EST
Change (% chg)

$-0.01 (-1.54%)
Prev Close
$0.34
Open
$0.34
Day's High
$0.35
Day's Low
$0.33
Volume
214,034
Avg. Vol
567,952
52-wk High
$2.60
52-wk Low
$0.31

Chart for

About

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has... (more)
No analyst recommendations are available for .

Overall

Beta: 1.35
Market Cap(Mil.): $4.73
Shares Outstanding(Mil.): 14.02
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 29.40 15.80
EPS (TTM): -- -- --
ROI: -- 10.14 12.07
ROE: -- 15.42 16.02

BRIEF-Atossa Genetics posts Q3 loss per share ‍$0.18​

* Atossa Genetics announces third quarter 2017 financial results and provides company update

Nov 14 2017

BRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filing

* Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics Inc, as of Oct 26 - SEC filing Source text: (http://bit.ly/2iIbgjU) Further company coverage:

Nov 09 2017

BRIEF-Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics

* Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​ Source text: (http://bit.ly/2z0yYCe) Further company coverage:

Oct 31 2017

BRIEF-Atossa Genetics announces pricing of $5.1 million public offering

* Atossa Genetics announces pricing of $5.1 million public offering of common stock

Oct 26 2017

BRIEF-Atossa Genetics announces proposed public offering of common stock

* Atossa Genetics announces proposed public offering of common stock

Oct 25 2017

BRIEF-Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

* Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

Sep 25 2017

BRIEF-Atossa Genetics files for mixed shelf of upto $50 million

* Atossa Genetics Inc files for mixed shelf of upto $50 million - SEC filing‍​ Source text: [http://bit.ly/2xmdyOY] Further company coverage:

Sep 22 2017

BRIEF-Atossa Genetics reports Q2 ‍loss per share $0.64​

* Atossa Genetics announces second quarter 2017 financial results and provides company update

Aug 14 2017

BRIEF-Atossa Genetics receives positive safety committee assessment

* Atossa genetics says received positive interim safety assessment of first cohort receiving proprietary oral endoxifen in phase 1 dose escalation study Source text for Eikon: Further company coverage:

Jun 26 2017

Earnings vs. Estimates